164 related articles for article (PubMed ID: 12435520)
21. Commentary: unapproved uses, dosages, or indications in dermatology: a physician's reference.
Wolf R
Clin Dermatol; 2002; 20(5):465-6. PubMed ID: 12435515
[No Abstract] [Full Text] [Related]
22. Evaluating lipid-lowering trials in the twenty-first century.
Roberts WC
Am J Cardiol; 2009 May; 103(9):1325-8. PubMed ID: 19406281
[No Abstract] [Full Text] [Related]
23. Cryosurgery: unapproved uses, dosages, or indications.
Dawber R
Clin Dermatol; 2002; 20(5):563-70. PubMed ID: 12435527
[No Abstract] [Full Text] [Related]
24. Current approach to the man with acute phase Peyronie's disease--case presentation and discussion.
Levine LA
J Sex Med; 2011 Jun; 8(6):1556-8; quiz 1559. PubMed ID: 21631731
[No Abstract] [Full Text] [Related]
25. Unapproved dermatologic indications for H2 receptor antagonists, cromolyn sodium, and ketotifen.
Paquette D; Rothe MJ
Clin Dermatol; 2000; 18(1):103-11. PubMed ID: 10701091
[No Abstract] [Full Text] [Related]
26. Phototherapy, photochemotherapy, and photodynamic therapy: unapproved uses or indications.
Ledo E; Ledo A
Clin Dermatol; 2000; 18(1):77-86. PubMed ID: 10701088
[No Abstract] [Full Text] [Related]
27. Pruritus: unapproved treatments or indications.
Millikan LE
Clin Dermatol; 2000; 18(2):149-52. PubMed ID: 10742622
[No Abstract] [Full Text] [Related]
28. Hair repigmentation in a hepatitis C patient treated with interferon and ribavirin.
Kavak A; Akcan Y; Korkmaz U
Dermatology; 2005; 211(2):171-2. PubMed ID: 16088172
[No Abstract] [Full Text] [Related]
29. Progress in systemic sclerosis: novel therapeutic paradigms.
Varga J
Curr Rheumatol Rep; 2000 Dec; 2(6):481-5. PubMed ID: 11123101
[No Abstract] [Full Text] [Related]
30. Why taper prednisone in dermatology?
Blair M
JAAPA; 2001 Apr; 14(4):72. PubMed ID: 11521370
[No Abstract] [Full Text] [Related]
31. [Efficacy of and indications for IFN retreatment of patients with chronic hepatitis C].
Iyoda K; Kato M
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):502-5. PubMed ID: 15359850
[No Abstract] [Full Text] [Related]
32. [Cutaneous side effects of interferons].
Paquet P; Piérard-Franchimont C; Arrese JE; Piérard GE
Rev Med Liege; 2001 Oct; 56(10):699-702. PubMed ID: 11765581
[TBL] [Abstract][Full Text] [Related]
33. Tigecycline (Tygacil).
Obstet Gynecol; 2006 Jan; 107(1):178-80. PubMed ID: 16394058
[No Abstract] [Full Text] [Related]
34. Mycophenolate in dermatology.
Liu V; Mackool BT
J Dermatolog Treat; 2003 Dec; 14(4):203-11. PubMed ID: 14660264
[TBL] [Abstract][Full Text] [Related]
35. Rituximab as effective treatment in a case of severe subcutaneous nodulosis in rheumatoid arthritis.
Sautner J; Rintelen B; Leeb BF
Rheumatology (Oxford); 2013 Aug; 52(8):1535-7. PubMed ID: 23329684
[No Abstract] [Full Text] [Related]
36. Off-label uses of biologics in dermatology: interferon and intravenous immunoglobulin (part 1 of 2).
Smith DI; Swamy PM; Heffernan MP
J Am Acad Dermatol; 2007 Jan; 56(1):e1-54. PubMed ID: 17190617
[TBL] [Abstract][Full Text] [Related]
37. Corticosteroid injection for carpal tunnel syndrome.
Boyer MI
J Hand Surg Am; 2008 Oct; 33(8):1414-6. PubMed ID: 18929212
[No Abstract] [Full Text] [Related]
38. A review of clinical experience and recommendations for improving patient care.
Weiss J
Cutis; 2005 Feb; 75(2 Suppl):32-8; discussion 39. PubMed ID: 15773541
[TBL] [Abstract][Full Text] [Related]
39. Ocular herpes simplex.
Barker N
Clin Evid; 2002 Jun; (7):597-604. PubMed ID: 12230686
[No Abstract] [Full Text] [Related]
40. Intralesional drug therapy in dermatology.
Deshmukh NS; Belgaumkar VA; Mhaske CB; Doshi BR
Indian J Dermatol Venereol Leprol; 2017; 83(1):127-132. PubMed ID: 27647355
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
